Unique ID issued by UMIN | UMIN000023905 |
---|---|
Receipt number | R000027528 |
Scientific Title | Therapeutic Strategy for Efficient Reduction of Serum Uric Acid Levels with Allopurinol versus Benzbromarone in Hyperuricemic Patients with Essential Hypertension-A Randomized Crossover Study (TERAO study) |
Date of disclosure of the study information | 2016/09/02 |
Last modified on | 2016/09/02 11:28:07 |
Therapeutic Strategy for Efficient Reduction of Serum Uric Acid Levels with Allopurinol versus Benzbromarone in Hyperuricemic Patients with Essential Hypertension-A Randomized Crossover Study (TERAO study)
TERAO study
Therapeutic Strategy for Efficient Reduction of Serum Uric Acid Levels with Allopurinol versus Benzbromarone in Hyperuricemic Patients with Essential Hypertension-A Randomized Crossover Study (TERAO study)
TERAO study
Japan |
hyperuricemia
Medicine in general | Cardiology | Endocrinology and Metabolism |
Adult |
Others
NO
To compare the effects of different drugs used to treat hyperuricemia on cardiovascular risk factors, we designed a crossover study employing both a urate transporter-1 inhibitor (benzbromarone) and xanthine oxidase inhibitor (allopurinol).
Efficacy
Confirmatory
Explanatory
Not applicable
the change of serum and urine urate and proteinuria
none
Interventional
Cross-over
Randomized
Individual
Open -no one is blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
No need to know
2
Treatment
Medicine |
We randomized 7 consecutive patients with microalbuminuria having hypertension (>140/90 mm Hg or taking anti-hypertensive medications) and hyperuricemia (serum uric acid levels >7 mg/dL) to receive either benzbromarone 25 mg once daily for the first four weeks of the study.
We randomized 7 consecutive patients with microalbuminuria having hypertension (>140/90 mm Hg or taking anti-hypertensive medications) and hyperuricemia (serum uric acid levels >7 mg/dL) to receive allopurinol 200 mg twice daily for the first four weeks of the study.
20 | years-old | <= |
Not applicable |
Male and Female
patients having hypertension (>140/90 mm Hg or taking anti-hypertensive medications) and hyperuricemia (serum uric acid levels >7 mg/dL).
patients in whom informed consent could not be received.
14
1st name | |
Middle name | |
Last name | Sunao Kojima |
Kumamoto University
Cardiovascular medicine
1-1-1 Honjo, Chuo-ku Kumamoto
096-373-5175
kojimas@kumamoto-u.ac.jp
1st name | |
Middle name | |
Last name | Sunao Kojima |
Kumamoto University
Cardiovascular medicine
1-1-1 Honjo, Chuo-ku Kumamoto
096-373-5175
kojimas@kumamoto-u.ac.jp
Division of Cardiovascular Medicine, Kumamoto University
none
Self funding
Terao Hospital
NO
熊本大学医学部附属病院
寺尾病院
2016 | Year | 09 | Month | 02 | Day |
Unpublished
Completed
2013 | Year | 06 | Month | 12 | Day |
2013 | Year | 06 | Month | 12 | Day |
2016 | Year | 03 | Month | 31 | Day |
2016 | Year | 03 | Month | 31 | Day |
2016 | Year | 06 | Month | 30 | Day |
2016 | Year | 07 | Month | 01 | Day |
2016 | Year | 09 | Month | 02 | Day |
2016 | Year | 09 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027528